Abstracts XIX Brazilian Congress of Nuclear Medicine

7. ONCOLOGY

Scintigraphic detection of breast lesions has been performed with many radiopharmaceuticals, including [Tc-99m]sestamibi, the most widely used. The purpose of this study was to evaluate the sensitivity and specificity of [Tc-99m]sestamibi mammoscintigraphy (MS) in patients (pts)with axillary or breast lesions. Fifty five female patients were studied (mean age 50.5 yrs), with clinical diagnosis of a palpable mass or suspicious mammographic findings. The size of the tumor ranged from 0.5 to 20 cm. Ten minutes after an intravenous injection of 740 MBq (20 mCi) of [Tc-99m]sestamibi, images were acquired in the posterior oblique and lateral projections of the breasts and anterior projection of the axillae. [Tc-99m] sestamibi uptake was graded as mild, moderate or marked. All pts underwent fine needle biopsy or lesion resection. MS was abnormal in 34 pts (4 mild, 18 moderate and 12 marked): 29 pts with histopathology of breast carcinoma and 5 with benign disease. Twenty one pts had normal MS, and only one had carcinoma at histopathology (non-palpable tumor). MS sensitivity was 96.7%, specificty 80%, positive predictive value 85.3% and negative predictive value 95.2%. MS was very sensitive in the diagnosis of primary breast carcinoma. However, false positive results due to uptake in benign lesions of the breast are not infrequent.

1.Cardiology |  2.Endocrinology | 3.Equipment: Quality Control | 4.Gastroenterology |  5.Infectious Diseases |  6.Nephro-Urology |  7.Oncology |  8.Orthopheadics | 9.PET/SPECT | 10.Pneumology |  11.Radiobiology |  12.Radiopharmacy |  13.Special Clinical Applications |  14.Neuropsychiatry |